Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines. Issue 49 (17th November 2020)

• Record Type: Journal Article
• Authors: Gurwith, Marc; Condit, Richard C.; Excler, Jean-Louis; Robertson, James S.; Kim, Denny; Fast, Patricia E.; Drew, Stephen; Wood, David; Klug, Bettina; Whelan, Mike; Mallett Moore, Tamala; Khuri-Bulos, Najwa; Smith, Emily R.; Chen, Robert T; Kochhar, Sonali
• Is Part Of: Vaccine. Volume 38:Issue 49(2020)
• Page Start: 7702
• Page End: 7707
• Publication Date: 2020-11-17
• Subjects: Brighton Collaboration -- CEPI -- COVID-19 -- Vaccine -- Benefit-risk -- Safety -- Live -- Attenuated -- Viral -- Template; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2020.09.042
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of live-attenuated viral vaccines. This will help key stakeholders assess potential safety issues and understand the benefit-risk of such vaccines. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed live-attenuated viral vaccines.